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Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare, but severe thrombotic microangiopa-
thy. In roughly two thirds of the patients, mutations in complement genes lead to uncon-
trolled activation of the complement system against self cells. Recently, aHUS patients
were described with deficiency of the fibrinolytic protein plasminogen. This zymogen and its
protease form plasmin have both been shown to interact with complement proteins in the
fluid phase. In this work we studied the potential of plasminogen to restrict complement
propagation. In hemolytic assays, plasminogen inhibited complement activation, but only
when it had been exogenously activated to plasmin and when it was used at disproportion-
ately high concentrations compared to serum. Addition of only the zymogen plasminogen
into serum did not hinder complement-mediated lysis of erythrocytes. Plasminogen could
not restrict deposition of complement activation products on endothelial cells either, as was
shown with flow cytometry. With platelets, a very weak inhibitory effect on deposition of C3
fragments was observed, but it was considered too weak to be significant for disease patho-
genesis. Thus it was concluded that plasminogen is not an important regulator of comple-
ment on self cells. Instead, addition of plasminogen was shown to clearly hinder platelet
aggregation in serum. This was attributed to plasmin causing disintegration of formed plate-
let aggregates. We propose that reduced proteolytic activity of plasmin on structures of
growing thrombi, rather than on complement activation fragments, explains the association
of plasminogen deficiency with aHUS. This adds to the emerging view that factors unrelated
to the complement system can also be central to aHUS pathogenesis and suggests that
future research on the mechanism of the disease should expand beyond complement
dysregulation.
Introduction
Plasminogen is a 92-kDa glycoprotein that circulates the vasculature at a concentration of 0.2
mg/ml (2 μM). The closed structure enables plasminogen to maintain its zymogenic form, but
removal of an N-terminal peptide exposes the cleavable Arg561-Val562 bond and allows some
plasmin activation by tissue- or urokinase-type plasminogen activators (tPA and uPA) [1].
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Efficient formation of plasmin, however, requires that plasminogen and tPA form a ternary
complex with fibrin. Plasmin can also be produced on endothelial cells on which Annexin II—
S100A10 heterotetramers co-localize plasminogen with tPA or receptor-bound uPA [2]. By
cleaving fibrin, plasmin enhances its own activation as the exposed C-terminal lysines function
as binding sites for new plasminogen and tPA molecules [3]. The thrombin-activatable fibrino-
lysis inhibitor (TAFI) counteracts this effect by removing lysines. The primary physiological
inhibitor of plasmin in plasma is α2-antiplasmin (α2-AP; 1 μM), that forms stable inactive
complexes with free plasminogen [4]. α2-AP can also be covalently linked to fibrin to modulate
fibrinolysis [5]. Plasminogen activator inhibitor 1 (PAI-1) exerts its effect indirectly by inacti-
vating the activators of plasminogen.
Plasmin activity has been implicated in, for example, tissue remodeling, wound healing,
angiogenesis, and cancer invasion [6] but also in cell injury. This can probably be attributed to
the ability of plasmin to degrade components of the extracellular matrix and basal membrane,
and to activate matrix metalloproteases. Plasmin is probably best known for its critical role in
fibrinolysis. With its ability to digest fibrin fibers, plasmin controls the extent of coagulation
and is of central importance for solubilization of blood clots. Therefore it is somewhat surpris-
ing that plasminogen deficiency as a sole abnormality is mainly related to ligneous conjunctivi-
tis [7], but does not seem to increase risk of thrombosis in human subjects [8]. Interestingly,
plasminogen deficiency was recently associated with the disease atypical hemolytic uremic syn-
drome (aHUS) [9].
aHUS is a rare systemic disease characterized by hemolysis, thrombocytopenia and renal
impairment [10]. Central to aHUS is dysregulation of the complement system on host cells
[11]. Complement is a network of over 30 serum proteins that normally act, for example, in
protecting the body against invading microbes and in removal of damaged cells (reviewed by
Ricklin et al. [12]). Different arms of the system are activated on various targets, leading to
marking these surfaces with the opsonin C3b and assembly of lytic pores, i.e. C5b-9 complexes,
into cell membranes. To prevent harmful complement attack against normal self cells, its acti-
vation is tightly controlled by multiple soluble and membrane-bound regulators. With the dis-
ease aHUS, roughly 70% of patients have one or several abnormalities of complement genes
[13]: loss-of-function mutations in regulators and gain-of-function mutations in activators
lead to uncontrolled activation of the complement cascade [10].
Considering the thrombotic nature of aHUS, it is not surprising that, besides complement
factors, an increasing number of proteins of the coagulative and fibrinolytic systems are being
linked to the disease. The most recent example is plasminogen with four aHUS-patients show-
ing variation in the respective protein encoding gene [9]. Three of the plasminogen variants
reported were known from earlier literature to cause plasminogen deficiency, and the authors
suggested that in these aHUS-cases degradation of thrombi was compromised due to reduced
fibrinolytic activity. Support for impaired fibrinolysis to be involved in aHUS was obtained in a
study where the ratio of antifibrinolytic PAI-1 to profibrinolytic tPA was shown to be markedly
increased in patient biopsies at mRNA-level [14]. Data on fibrinolysis in typical HUS, on the
other hand, is controversial [9]. In some aHUS-patients, a prothrombotic state of endothelial
cells and platelets due to mutations in the gene encoding diacylglycerol kinase epsilon (DGKε)
seems to cause the disease [15]. Further, the coagulation factor XII and the anticoagulant glyco-
protein thrombomodulin have been associated with aHUS [9, 16, 17].
Versatile crosstalk has been proposed to exist between the coagulation and complement sys-
tems [18, 19]. Of the aHUS-associated coagulation pathway proteins, factor XII, for example,
activates C1 [20] and thrombomodulin assists in inhibition of C3b, C3a, and C5a [16]. Weak
enhancement of cleavage of purified C3b in the fluid phase has been reported for the newly
aHUS-linked protein plasminogen as well [21]. As for plasmin, this powerful protease cleaves
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both intact and activated forms of multiple complement proteins [21–28]. Streptokinase activa-
tion of plasminogen to plasmin has, for example, been shown to reduce the activities of the cen-
tral complement members C1, C2, C3 and C4 [22]. The physiological relevance of the
interactions of plasmin with complement has been experimented mainly in bacterial settings,
with several studies showing plasmin-mediated reduction in C3b-deposition [29–31]. Plasmin
has also been reported to inhibit complement mediated erythrocyte lysis in highly diluted
human serum [21]. In all these assays, however, plasmin was artificially activated. Multiple bac-
teria possess specific proteins with which the plasminogen acquired on their surfaces could be
activated to plasmin, at least during some phase of infection [32]. Erythrocytes, on the other
hand, do not practically bind plasminogen [33]. These earlier results led us to ask whether plas-
minogen could regulate complement activation on surfaces of human cells capable of both
binding and activating this zymogen.
Of the three types of cells damaged in aHUS, abnormal complement activation is involved
in injury to endothelial cells especially lining the glomerular microvasculature [10] and to
platelets [34]. Hemolysis in aHUS-patients, on the other hand, is generally referred to be
mechanical in nature [13], although a sensitizing cell stiffening role for C3b-deposition in
erythrocyte rupture cannot be ruled out [35]. Fibrin, an important constituent of thrombi, has
also been claimed to activate the complement system [36, 37], although it has not been consid-
ered a target in aHUS. In this work, we set out to experiment the potential of plasminogen to
regulate complement activation on the surfaces relevant to aHUS. Our results show that, in
conditions resembling those found physiologically, plasminogen does not restrict propagation
of the complement cascade on erythrocytes or endothelial cells but has a very modest inhibi-
tory effect on complement activation on platelets.
Materials and Methods
Ethics Statement
The appropriate Institutional Review Board of the University of Helsinki had approved the
extraction of and the studies with the human umbilical vein endothelial cells (HUVECs), and
the protocols using blood had been approved by the Section for Research of the Helsinki Uni-
versity Central Hospital Laboratory (project TYH7214). A written informed consent was
obtained from all donors in accordance to the Declaration of Helsinki.
Materials
Plasminogen, plasmin, human HMW urokinase, and human tissue plasminogen activator
(tPA) were fromMolecular Innovations. Plasminogen and plasmin were also purified / pre-
pared from human plasma (see below). Human fibrinogen and alpha thrombin were from
Enzyme Research. S-2251 was from Chromogenix. BSA was from Biowest. Goat (GPMG-80A)
and sheep (PAHPG-S) anti-human plasminogen antibodies were from ICL Lab and Haemato-
logic Technologies, respectively. Trypsin, α-chymotrypsin, mannan, Zymosan A, D-Ala-Leu-
Lys-7-amido-4-methylcoumarin, Triton X-100, and cold water fish gelatin were from Sigma
Aldrich. Calcein AM was from BD Biosciences. Amboceptor, the guinea pig anti-sheep eryth-
rocyte antibody, was of in-house origin from Aurora Hospital in Helsinki. Rat anti-CD59 anti-
body (YHT53.1) had been earlier produced in-house with a cell line originally kindly provided
by Professor H. Waldmann (University of Oxford, England). HUVECs (passage 2) were the
most generous gift fromMikko Helenius (University of Helsinki, Finland) and had been
extracted from healthy human subjects as previously described [38]. EndoGRO-LS cell culture
medium was fromMerck Millipore. The RED-NHS kit for labeling proteins with NT-647 was
from NanoTemper Technologies GmbH. Rabbit anti-C5b-9 antibody (A227) and human
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Factor H were from Complement Technology. PE/Cy5-labeled anti-P-selectin antibody
(304908) was from BioLegend. Hirudin blood tubes were from Roche.
Preparation of proteins
Plasminogen was extracted from citrated human plasma with Lysine HyperD affinity matrix
(PALL Life Sciences) according to manufacturer’s instructions, followed by gel filtration
(HiLoad1 16/60 Superdex1 200 pg, GE Healthcare) into 20 mMHepes, pH 7.4, 144 mM
NaCl, 2.5 mMMgCl2.
C3 and FH19-20 were prepared mainly as previously described [39, 40].
IgG was purified from human plasma with Protein G Sepharose 4 Fast Flow (Amersham
Pharmacia Biotech AB) mainly according to the manufacturer’s instructions, followed by gel
filtration into PBS. Heat aggregated immunoglobulin (HAIgG) was prepared by incubating
this IgG for 20 min at 63°C.
To produce plasmin, plasminogen (1 mg/ml) was mixed with urokinase (16 μg/ml) in
Hepes buffer on ice, transferred to 37°C for 5.5 min and then frozen on dry ice. The concentra-
tion of active plasmin was estimated to be 70% by comparing to the ability of a commercial
product to cause a change in absorbance for the plasmin substrate S-2251 at 405 nm.
Microtiter plate assay with fibrin coating
Microtiter plate wells (Nunc Maxisorp) were coated with 100μl of HAIgG (30 μg/ml), mannan
(200 μg/ml), fibrinogen (100 μg/ml), or BSA (20 μg/ml) in PBS at 22°C for at least 3 hours.
Fibrinogen-coated wells were treated with thrombin (100 μl, 5 units/ml) for 1 hour at 37°C.
Wells were blocked with 0.5% BSA in PBS overnight at 4°C. After multiple rinses with PBS,
wells were incubated with 2.5% serum diluted in Hepes buffer (20 mMHepes, pH 7.4, 144 mM
NaCl, 2.5 mMMgCl2, 5 mM CaCl2) for 30 min at 37°C. Formation of C3a was analyzed using
the MicroVue C3a Plus EIA kit (Quidel).
Preparation of fibrin beads
3 ml of fibrinogen (10 mg/ml) and 1 ml of thrombin (35 units/ml) in Hepes buffer were mixed
and fibrin formation allowed for 1 hour at 37°C. The clot was frozen on dry ice, lyophilized for
44 hours and finally ground into very fine powder.
Plasminogen activation on fibrin beads
Fibrin beads or human erythrocyte ghosts (both 120 μl/ml) in Hepes buffer with 1 mg/ml BSA
were mixed with 3 μl of plasminogen (3 mg/ml) and incubated at 22°C for 40–60 min. Samples
were washed with 1 ml of buffer. 400 μl of buffer was added, followed by 20 μl of plasmin sub-
strate (D-Ala-Leu-Lys-7-amido-4-methylcoumarin, 1 mM) and 20 μl of tPA (20 units/ml). As
a positive control, 3 μl of plasmin (8 μM) was used. After 30–45 min incubation at 22°C, the
fluorescence of 100 μl-sample mixtures were measured with ex/em values 355/460nm (FLUOs-
tar OPTIMA, BMG Labtech).
Preparation of partially plasminogen-depleted serum
Goat anti-plasminogen antibody was coupled to CNBr-activated beads (GE Healthcare)
according to manufacturer's instructions. The beads were washed into PBS, mixed with serum,
and incubated on ice for 30 min with occasional stirring. The beads were centrifuged and the
supernatant serum collected. By comparing the absorbances (at 280 nm), the depletion was
estimated to dilute the serum by 40%. The amount of plasminogen removed from the partially
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depleted serum was analyzed with a dot blot using a sheep anti-plasminogen antibody and
found to be 70, 70 and 50% in the different batches prepared.
Complement activation in presence of fibrin beads
Activated Zymosan (0.2 mg) and fibrin beads (0.5 mg) were washed into Hepes buffer contain-
ing 1 mg/ml BSA. The beads were mixed with normal or partially plasminogen-depleted serum
(final concentration 44% and volume 80 μl) and incubated at 37°C for 30 min. The sera were
analyzed for complement activation as follows: (1) Formation of C3a was measured using the
MicroVue C3a Plus EIA kit (Quidel). (2) Residual hemolytic activity was determined by incu-
bating Es (1.5%) with factor H fragment comprising domains 19 and 20 (FH19-20; 60 μg/ml)
and serum (4%) at 37°C for 25 min, and measuring absorbance of the supernatants at 414 nm.
Hemolysis inhibition by plasmin
Hemolysis assays were done essentially as previously described [21]. 1% sheep erythrocytes
(Es) were washed into 0.9% NaCl and mixed 1:1 with amboceptor (diluted 1:100 in 0.9%
NaCl). Sensitized Es were washed into Hepes buffer. Potential inhibitor, human serum and Es
were mixed in tubes on ice and then incubated at 37°C for 22 min. Samples were centrifuged
for 3 min with 800 g. Absorbances of supernatants were measured at 414 nm. Within each
sample, the erythrocyte and serum contents (volume-%) were kept equal, but they changed
between the samples being 1.3, 1.5, 2.5, or 5.0%.
Experiments with endothelial cells
HUVECs were cultured in serum-containing medium until passage 5 or 6. Cells from nearly
confluent plates were detached and washed into PBS containing or not 0.1% gelatin. In the
plasminogen binding assay, 3105 cells were incubated with NT-647-labeled plasminogen (0.3
mg/ml) in 100 μl PBS at 37°C for 30 min. Plasminogen binding was determined using CyAn™
ADP Analyzer.
For the complement activation assay, a fluorescent compound was introduced into the
HUVECs by incubating 2106 cells in 600 μl gelatin PBS containing 10 μg Calcein AM at 37°C
for 30 min, followed by two washes with gelatin PBS. In the cell lysis assay, samples of 4104
cells in a final volume of 80 μl were used. Cells were added with plasminogen (0.3 mg/ml) or
the controls factor H (0.2 mg/ml) or BSA (0.3 mg/ml). Serum was added to a final concentra-
tion of 30%. As serum from healty human subjects does not lead to complement activation on
endothelial cells [41] the cascade was initiated with anti-CD59 antibody, which activates the
complement system through the classical pathway in addition to interfering with normal func-
tion of the complement regulator CD59. To the total lysis control sample, 3 μl of 9% Triton
X-100 was added to force complete lysis. HUVECs were incubated at 37°C for 12 min. Cells
were centrifuged and relative fluorescence of each supernatant measured at ex/em values 485/
520nm (FLUOstar OPTIMA, BMG Labtech).
Platelet isolation
Blood was collected into citrate tubes (Vacuette, 9 ml, Greiner Bio-One), followed by centrifu-
gation at 200 g for 20 min at 22°C (no brake). Platelet rich plasma was mixed with citrate buffer
(9.4 mM citrate, 4.8 mM citric acid, 17.4 mM dextrose, 145 mMNaCl, pH 6.5). Citric acid
(0.25 M) was added to lower the pH of the sample to about 6.5 to prevent platelet activation
during washes. Platelets were centrifuged at 440 g for 20 min, followed by two further washes
and a final resuspension into modified Tyrode's buffer (137 mMNaCl, 2.7 mM KCl, 984 mM
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MgCl2, 7 mMHepes, 0.35% BSA, 5.5 mM dextrose, 2 mM CaCl2, pH 7.4). Platelet concentra-
tion was determined with Sysmex KX-21 Hematology analyzer.
Plasminogen binding to platelets
Platelets (4106 cells) were incubated with or without NT-647-labeled plasminogen (0.3 mg/
ml) for 30 min at 22°C. Platelets were diluted in PBS and plasminogen binding determined
immediately using the CyAn™ ADP Analyzer. Data was analyzed with the FlowJo-software.
C3-fragment deposition on platelets
Platelets (4106 cells) were preincubated or not with plasminogen (0.2 mg/ml which equals the
plasma concentration) at 22°C for 15 min. FH19-20 (0.2 mg/ml) was added to all samples to
activate complement. In the negative control, activity was prevented using 10 mM EDTA. NT-
647-labeled C3 (0.4 mg/ml) was added to all samples, followed by 30 μl of serum and a 15 min
incubation at 37°C. Complement propagation was stopped with 10 mM EDTA and cells
diluted in 2–4 ml PBS, followed by immediate flow cytometry analysis with the CyAn™ ADP
Analyzer. Geometric mean fluorescence values were extracted from the flow cytometry data
with the FlowJo-software.
Platelet activation
Platelets (4106 cells) were preincubated with plasminogen (0.2 mg/ml), hirudin (10 μg/ml),
hirudin (10 μg/ml) and FH19-20 (0.1 mg/ml), or buffer at 22°C for 15 min. Serum (or buffer)
was added to a final concentration of 30% and platelets incubated at 37°C for 15 min. EDTA
was added (10 mM final concentration), followed by 6 μl of anti-P-selectin antibody. Samples
were incubated at 4°C for about 1 hour, and then analyzed by flow cytometry.
Platelet aggregation
Platelets (6106 cells) in 30 μl of modified Tyrode's buffer were pipetted into wells of a 96-well
microtiter plate. Plasminogen (2 μM) or buffer was added, and platelets were incubated at 22°C
for at least 10 min. Alternatively, platelets were preincubated with FH19-20 (0.2 mg/ml).
Serum mixed with hirudin (10 μg/ml) or buffer was added to the platelets to a final concentra-
tion of 30%. The platelets were agitated at 37°C in a microplate reader (FluoStar OPTIMA,
BMG Labtech) with double orbital shaking mode. Absorbances at 405 nm were read every 19
seconds throughout the 20 min experiment.
Statistical Methods
GraphPad Prism software was used to assess the statistical significance of observed differences.
Both one-way ANOVA with Tukey's multiple comparison post-test and one-sample t-test
were used.
Results
Complement system does not activate on fibrin surfaces
As fibrin has been claimed to activate the complement system [36, 37] and as it is a major site
of plasminogen binding and activation in vivo, we considered it a possible model with which
the effect of plasminogen on complement activation on a surface could be studied. Here, and in
other assays of complement activation, we used serum and purified plasminogen. As serum
contains plasminogen activators—albeit at lower levels than plasma—transformation of added
Plasminogen and Complement Activation on Cells
PLOS ONE | DOI:10.1371/journal.pone.0143707 December 4, 2015 6 / 19
plasminogen into plasmin on surfaces capable of plasminogen binding and activation was
plausible. Further, some interfering reaction products might have been introduced into serum
due to strong activation of coagulation during serum preparation.
First we coated fibrinogen on a microtiter plate and treated it with thrombin to make it
more fibrin-like. When these wells were incubated with diluted serum, no difference in concen-
tration of the complement activation product C3a could be observed compared to the negative
control BSA (Fig 1A). With the positive controls, i.e. the known complement activators HAIgG
and mannan, levels of C3a were increased (Fig 1A).
In vivo, fibrin appears as 3-D fibers, and we asked whether the lack of complement activa-
tion in our plate assay was due to an erroneous model. We next produced fibrin in the form of
beads. These were considered a more suitable model of fibrin, since plasminogen bound to
them could be further activated by tPA to plasmin as verified by cleavage of a plasmin substrate
(Fig 1B). Ghosts of human erythrocytes, which practically do not bind plasminogen [33], were
used as a negative control and expectedly showed no plasmin activity in the assay (Fig 1B).
Next it was reasoned that in the case plasminogen regulated complement on fibrin, then in
normal serum complement activation would not occur on our beads. We therefore prepared
serum that was mostly depleted of plasminogen. When fibrin beads were incubated with nor-
mal or the partially depleted serum, no difference in C3a-levels compared to the negative con-
trol could be observed (Fig 1C). The hemolytic activities were not affected either (Fig 1D). In
contrast to this, incubation of normal and the partially depleted sera with the known comple-
ment activator Zymosan resulted in both increased production of C3a (Fig 1C) and loss of
hemolytic activity (Fig 1D).
Taken together, the inability of fibrin to induce complement activation prevented us from
using it as a model surface.
Plasmin does not inhibit complement activation on erythrocytes at
physiological concentrations
Of the cell types damaged in aHUS, erythrocytes have earlier been shown to be protected from
complement-mediated hemolysis by plasmin in highly diluted serum [21]. Also in our assay
plasmin (but not plasminogen) was observed to inhibit lysis of sensitized sheep erythrocytes
(Fig 2A). But even though major inhibition of lysis was attained with lower than or close to
physiological levels of plasminogen in both the reported [21] and our own assays, the amount
of plasmin added was not in proportion to the concentrations of erythrocytes and serum used.
For example, in the original assay described in the literature [21], 2 μM plasmin (as is found on
average in 100% plasma) was added to 0.8% serum, resulting in a 100-fold excess concentration
of plasmin compared to the serum used. Therefore we next fixed the amount of plasmin to a
constant value of 0.4 μM (20% of normal plasma level) and tested inhibition with increasing
concentrations of both erythrocytes and serum. Whereas most of hemolysis was prevented
when only 1.5% cells and serum were present, the inhibition was nearly completely lost in mix-
tures with a serum concentration of only 5% (Fig 2B). These results show that plasmin prevents
complement-mediated lysis only if the concentration of plasmin added exceeds multiple times
the level of natural plasminogen in serum.
We also tested two unrelated serine proteases, the digestive system enzymes α-chymotryp-
sin and trypsin, for their ability to affect hemolysis. Similar to plasmin, both α-chymotrypsin
and trypsin inhibited erythrocyte lysis at 1 μM concentrations (Fig 2C).
Taken together, these results confirm that plasmin (but not plasminogen) can inhibit hemo-
lysis, but suggest that this occurs only if plasmin is exogenously activated and added in dispro-
portionately high concentrations.
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Plasminogen does not inhibit complement activation on endothelial cells
Damage to endothelial cells in aHUS is thought to involve poor complement regulation on
them [42]. Unlike erythrocytes, endothelial cells are capable of not only binding but also of
activating plasminogen to plasmin on their surfaces [2]. We therefore asked if complement
activation could be regulated on endothelial cells by plasminogen. HUVECs were chosen as
model cells for our assays, and first, efficient binding of fluorescently labeled plasminogen to
these cells was confirmed with flow cytometry (Fig 3A). To study the effect of plasminogen on
complement activation on endothelial cells, a fluorescent compound was introduced into
HUVECs and its release during serum incubation used as a measure of complement cascade
propagation. When the effect of plasminogen on cell lysis was experimented, no inhibition
could be observed (Fig 3B), even though plasminogen was used in five times excess compared
to the serum added. The positive control factor H, on the other hand, efficiently inhibited
Fig 1. Complement system does not activate on fibrin surfaces. A: Formation of C3a in 2.5% serum incubated in wells coated with fibrin, the known
complement activators heat aggregated immunoglobulin (HAIgG) and mannan, and the negative control BSA. The assay was done three times with triplicate
measurements. B: Conversion of plasminogen to plasmin by tissue-type plasminogen activator (tPA) on fibrin beads. Formation of plasmin was followed by
measuring appearance of a fluorescent cleavage product. Preformed plasmin was used as a positive and human erythrocyte ghosts as a negative control.
The assay was done four times with single samples. C: Formation of C3a in normal and partially plasminogen-depleted serum incubated in the presence of
fibrin beads. Buffer added or not with Zymosan beads served as controls. Three independent assays were analyzed in duplicate. D: Residual hemolytic
activity of normal and partially plasminogen-depleted serum incubated in the presence of fibrin beads. Buffer added or not with Zymosan beads served as
controls. Three independent assays were analyzed in triplicate. (Data shown are mean values ± SD. **, P < 0.01; ***, P < 0.001; ns, not significant).
doi:10.1371/journal.pone.0143707.g001
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HUVEC lysis at levels similar to that of the 30% serum. These results indicate that plasminogen
does not inhibit complement activation on resting endothelial cells.
Plasminogen has a minor inhibitory effect on complement activation on
platelets
The third group of cells affected in aHUS, i.e. platelets, have an exceptionally high capacity for
plasminogen binding [33]. We used washed platelets in our assays, and first binding of
Fig 2. Plasminogen inhibits complement-mediated hemolysis only when artificially activated and
present at disproportionately high concentration. A: Inhibition of erythrocyte lysis in highly diluted (1.5%)
serum with increasing concentrations of added plasmin. Data for plasminogen, urokinase (used in
preparation of plasmin), and the negative control BSA are also shown. The assay was done six times. B:
Loss of plasmin-mediated inhibition of sheep erythrocytes (Es) with increasing concentration of serum. The
concentration of plasmin was kept at 20% of the physiological plasma level. The assay was done six times.
C: In addition to plasmin, hemolysis was inhibited with the proteases α-chymotrypsin and trypsin. The assay
was done three times in triplicate. (Data shown are mean values ± SD. *, P < 0.05; **, P < 0.01; ***,
P < 0.001; ns, not significant).
doi:10.1371/journal.pone.0143707.g002
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fluorescently labeled plasminogen to these cells was confirmed (Fig 4A). To activate the com-
plement system against platelets, we chose to use the C-terminal fragment of the complement
regulator factor H [43]. This was expected not to interfere with putative regulative properties
of plasminogen, since factor H and plasminogen interact with C3b noncompetitively through
Fig 3. Plasminogen does not inhibit complement activation on endothelial cells. A: Confirmation of
plasminogen binding to endothelial cells using flow cytometry. B: Effect of plasminogen on complement
activation on human umbilical vein endothelial cells (HUVECs). Cells were incubated or not with plasminogen
or the controls factor H or BSA prior to their exposure to 30% serum, followed by complement system
activation using an anti-CD59 antibody. Complement activation was determined by measuring the release of
a fluorescent compound introduced earlier into the cells. Representative data of an assay done five times are
presented. (Shown are average values ± SD. **, P < 0.01; ***, P < 0.001; ns, not significant).
doi:10.1371/journal.pone.0143707.g003
Plasminogen and Complement Activation on Cells
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separate binding sites [21]. Addition of FH19-20 to serum expectedly resulted in increased
deposition of C3 fragments on platelets (Fig 4B and 4C). When platelets were preincubated
with plasminogen, a slight inhibitory effect on C3 deposition was observed (Fig 4B and 4C).
In line with an earlier study [44], also in our assays exposure of platelets to sera was
observed to cause them to both get activated (Fig 5A) and aggregate (Fig 5B). As clotting blood
involves formation of thrombin, we suspected some of this potent platelet agonist to carry over
into the final product in preparation of serum. When hirudin was included in incubations,
both activation (Fig 5A) and aggregation (Fig 5B) of platelets in serum were prevented, show-
ing that thrombin was indeed responsible for the observed platelet-activating effect. When
platelets were incubated with plasminogen prior to exposure to serum, activation of platelets
was not affected (Fig 5A) but aggregation was markedly inhibited (Fig 5B).
It has previously been shown that thrombin-mediated platelet activation and aggregation
are enhanced in presence of complement [45], but purified C3a alone cannot induce aggrega-
tion [46]. In line with this, in our assays, complement activation as such (in the absence of spe-
cific platelet agonists) was not able to activate or aggregate platelets (Fig 6A and 6B).
Taken together, our results show that plasminogen has a very modest inhibitory effect on
complement deposition on platelets, but a prominent restrictive effect on aggregation.
Fig 4. Plasminogen has a very weak inhibitory effect on complement deposition on platelets. A: Confirmation of plasminogen binding to platelets using
flow cytometry. Shown is a representative histogram of four. B: A representative histogram showing very slight decrease in C3-fragment deposition on
platelets in serum due to addition of plasminogen. Complement system activation was enabled with FH19-20. Representative histograms of an assay done
five times are shown.C: Geometric mean fluorescence intensities of the assay described in (B). Values were compared to those for platelets incubated in the
presence of serum only (100%). Shown are average values ± SD. *, P < 0.05.
doi:10.1371/journal.pone.0143707.g004
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Discussion
aHUS features lysis of red blood cells, swelling and detachment of endothelial cells especially in
the glomeruli, and low platelet count due to their activation and consumption in thrombus for-
mation in microvasculature [10]. Whereas loss of proper control over complement activation
is long established to be central to aHUS [11], recent years have witnessed the emergence of
some coagulation and fibrinolytic proteins as mediators of the disease [9, 16, 17]. In this work
we studied the regulatory properties of the key fibrinolytic protein plasminogen on comple-
ment activation on surfaces relevant to aHUS. Our results show that plasminogen has a very
slight inhibitory effect on complement activation on platelets but not on erythrocytes or endo-
thelial cells.
Fig 5. Plasminogen inhibits platelet aggregation but not their activation in serum. A: The activating
effect of serum on platelets is counteracted with hirudin but not with plasminogen. Platelet activation was
determined by detecting exposure of the activation marker P-selectin of platelet surfaces using flow
cytometry. Shown are representative histograms of an assay performed three times. B: Inhibition of platelet
aggregation in serum by addition of plasminogen and hirudin. Complete aggregation was set to 100% light
transmission. Shown are mean values ± SD of an assay performed three times. For the time points marked
with the line segment, absorbance values for samples incubated or not with plasminogen were compared (*,
P < 0.05).
doi:10.1371/journal.pone.0143707.g005
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Fibrin is not considered a target of complement activation in aHUS, but it was included in
this study for its ability to bind and activate plasminogen. The discrepancy between earlier
work claiming complement activation on fibrin and our contradictory result can, at least par-
tially, be explained by experimental differences. For example, Endo et al. [37] used mouse
serum and untreated fibrinogen to show a modest increase above background in C4-deposi-
tion. Shats-Tseytlina et al. [36] observed an increase in production of C3a in the presence of a
fibrin clot compared to buffer alone, but no positive control was provided to judge the practical
Fig 6. Complement activation alone does not cause platelet activation or aggregation. Platelets were
incubated in serum and the complement system activated using FH19-20. Hirudin was included in the assays
to prevent thrombin-mediated activation.A: Flow cytometry analysis of exposure of the activation marker P-
selectin showed no activation of platelets due to complement activation. Shown are representative
histograms of an assay performed three times. B: Complement activation did not lead to platelet aggregation.
Complete aggregation was set to 100% light transmission. Shown are average values of an assay performed
three times.
doi:10.1371/journal.pone.0143707.g006
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relevance of this. In any case, an artificial fibrin surface created in a buffer is presumably not
representative of a clot in vivo. It lacks all the regulatory factors like α2-antiplasmin immobi-
lized on natural fibrin networks [5], which are likely to affect the function of at least plasmino-
gen on the fibers.
Of the cells affected in aHUS, erythrocytes have previously been shown to be protected from
complement-mediated lysis by the protease plasmin in highly diluted serum in vitro [21]. We
were able to confirm this (Fig 2A), but when serum concentration was increased, the protective
effect of plasmin was lost (Fig 2B). This was presumable mostly due to the need to overcome
the effect of the natural plasmin inhibitors of plasma. As erythrocytes are incapable of binding
plasminogen [33], they cannot provide protection from plasmin inhibitors present in plasma
and free plasmin is quickly inactivated by α2-antiplasmin [4]. Further, plasmin can deactivate
complement proteins in plasma [22], and it most likely functioned also in our serum assay by
digesting complement components. The central complement members C4 and C3 are rather
abundant proteins in plasma [47, 48], and increasing the serum concentration probably over-
whelmed the proteolytic capacity of plasmin added. Taken together, (i) plasminogen is not acti-
vated to plasmin on erythrocytes themselves, (ii) the inhibitors of plasma prevent diffusion of
active plasmin onto erythrocytes from other locations, and (iii) the abundance of target com-
plement proteins to be digested by plasmin necessitates many times more plasmin that can the-
oretically form of the 2 μM plasminogen that is naturally present. We seriously doubt that in
vivo a high enough local concentration of free plasmin could be attained on the surface of an
erythrocyte to allow significant effect on complement activation.
Endothelial cells, the other important group of cells severely damaged in aHUS, are capable
of not only binding but also of activating plasminogen on their surfaces [2]. Considering the
reported regulative properties of both plasminogen and plasmin on complement proteins
mainly in fluid phase [21–25, 27, 28], inhibition of complement propagation on endothelial
cell surfaces by plasminogen was seen highly plausible. Somewhat disappointingly, however,
no inhibition of HUVEC lysis in serum by adding plasminogen was observed (Fig 3B). This
can possibly be attributed to the very weak enhancing effect of the zymogen plasminogen on
C3b inactivation [21]. As we did not specifically activate the HUVECs and as only 30% serum
containing quite little tPA was used, not much conversion of plasminogen to the more effective
protease form plasmin is expected to have occurred. It is possible that on activated endothelial
cells and in the presence of higher serum levels a restrictive effect for plasminogen would be
observed. We did not, however, proceed to experiment the matter further. This was because
only a minor inhibitory effect for plasminogen on complement activation on platelets was
observed (Fig 4B), even though platelets have an exceptionally high plasminogen binding
capacity [33] and the activated state of platelets (Fig 5A) enhances plasmin formation on their
surfaces [49].
Similar to endothelial cells, platelets of aHUS-patients with mutations in the complement
regulator FH show excessive deposition of complement fragments on their surfaces [34]. Anal-
ysis of patient platelets has revealed the presence of markers of cell activation on them as well
[34]. These two processes, i.e. activation of the complement system and of platelets, seem to be
reciprocally intertwined [50]. On one hand, complement enhances thrombin- and ADP-medi-
ated platelet activation [45], whereas in the absence of C3, a modest attenuation of aggregation
is observed for platelets activated with an agonist peptide [51]. On the other hand, activation
of platelets can lead to activation of the complement system. For example, increased expression
of the receptor for C1q [52] enables triggering of the classical pathway of complement [53],
whereas exposure of P-selectin initiates the alternative pathway through binding C3b [50],
albeit weakly. All this suggests that by inhibiting complement activation, formation of thrombi
could be hindered at least to some extent.
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In our experiments incubation of platelets with plasminogen, prior to their exposure to
serum, inhibited deposition of C3 fragments on cells, but the effect was very weak (Fig 4). In
line with the earlier reported failure of C3a alone to bring about platelet aggregation [46],
directing complement attack against platelets in the absence of specific agonists (like thrombin)
was not enough to cause them to activate or aggregate (Fig 6A and 6B). This suggests only a
modifying role for complement on these processes. Considering that even in the case of com-
plete absence of complement activation only a modest attenuation of platelet aggregation has
been reported [51], the observed minor restriction of complement propagation by plasminogen
is not expected to be significant in vivo.
But why is plasminogen deficiency then associated with the thrombotic desease aHUS if not
for impaired complement regulation? Thrombi are composed of a mesh of fibrin fibers and
aggregated platelets. Besides causing inefficient fibrinolysis [9], plasminogen deficiency could
be involved in increased platelet aggregation. Interestingly, we observed a clear inhibitory
effect of plasminogen on platelet aggregation in serum (Fig 5B). As plasminogen was unable to
prevent the thrombin-mediated activation of platelets (Fig 5A), it must have exerted its effect
further downstream. Earlier it has been shown that the protease plasmin is capable of disinte-
grating existing platelet aggregates [54]. We used purified plasminogen in our assays, but for-
mation of plasmin was nevertheless likely. This was because the serum contained thrombin
(Fig 5) which activates platelets and increases plasminogen binding to them multifold [55], and
because platelet activation markedly enhances conversion of plasminogen to plasmin by tPA
[49]. Platelet disaggregation due to fibrinogenolysis [54], on the other hand, was unlikely since
we used only serum with very low fibrinogen content. Instead, plasmin might have cleaved
platelet surface receptors important for adhesion. Supporting this, plasmin has been shown to
severely impair the functional integrity of, for example, platelet surface glycoproteins Ib and
IIb/IIIa [56]. All in all, we propose that impaired control over thrombus growth either through
diminished fibrinolysis [9] or enhanced platelet aggregation explains the newly described link
between lack of plasminogen and aHUS.
But since plasminogen deficiency alone does not cause thrombosis [8], additional abnor-
malities are needed for the thrombotic events to manifest in plasminogen deficient aHUS-
patients. Albeit not due to impaired regulation by plasminogen, malfunction of the comple-
ment system could certainly be involved. Namely, the three aHUS-patients with variation in
plasminogen encoding gene were reported to carry one or two additional nucleotide changes in
the complement genes C1S, C3, C8A, CFHR5, and C9 [9]. It is difficult, however, to vision how
for example the reported gene variation causing C9 deficiency [9] could lead to excessive com-
plement activation. Importantly, most recent research on DGKε-associated aHUS [57] forces
us to acknowledge that the disease might evolve through mechanisms unrelated to the comple-
ment system. Loss of function of the kinase DGKε leads to decreased survival and a prothrom-
botic phenotype of at least endothelial cells rather than to complement-mediated lesions [57].
DGKε is also found in platelets [15] where it functions to inhibit their activation [58]. Data on
the response of the aHUS-patients with plasminogen deficiency to treatment with the thera-
peutic anti-C5 antibody eculizumab was not reported [9]. When available, it will help in
answering the question of involvement of complement activation in the disease pathogenesis
in these patients.
In conclusion, we have investigated the regulatory properties of plasminogen on comple-
ment activation on cell surfaces relevant to aHUS. The very weak inhibitory role of plasmino-
gen, observed only on platelets, suggests that plasminogen is not important in complement
regulation. Therefore the association of plasminogen deficiency with aHUS cannot be
explained by poor control over complement propagation. Instead, plasminogen was shown to
have a marked inhibitory effect on platelet aggregation in serum. We propose that, in aHUS
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patients with a reduced level of plasminogen, the lack of this zymogen leads to reduced proteo-
lytic activity of plasmin and thereby growth of thrombi in the microvasculature. Besides
impaired plasmin activity, the possibility of simultaneous malfunction of the complement
system in these patients remains. The emergence of non-complement proteins as mediators
of aHUS, however, prompts future research to broaden the scope outside of complement
dysregulation.
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